Immuneering Corporation Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.52 | -$0.52 | -$0.52 |
| Q2 2024 | 5 | -$0.59 | -$0.50 | -$0.55 |
| Q3 2024 | 3 | -$0.43 | -$0.43 | -$0.43 |
| Q1 2025 | 4 | -$0.37 | -$0.37 | -$0.37 |
| Q2 2025 | 4 | -$0.34 | -$0.34 | -$0.34 |
| Q3 2025 | 4 | -$0.35 | -$0.35 | -$0.35 |
| Q4 2025 | 4 | -$0.39 | -$0.39 | -$0.39 |
Immuneering Corporation Earnings Date And Information
Immuneering Corporation last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.47 earnings per share for the quarter, topping analysts' consensus estimates of $-0.51 by $0.04. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Immuneering Corporation has generated $-2 earnings per share over the last year ($-1.88 diluted earnings per share) and currently has a price-to-earnings ratio of -1.41. Immuneering Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
Immuneering Corporation Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/06/2024 | Q2 2024 | -$0.51 | -$0.47 | 0.04 | $0 | $0 |
| 05/07/2024 | Q1 2024 | -$0.45 | -$0.49 | -0.04 | $0 | |
| 03/01/2024 | Q4 2023 | -$0.48 | -$0.52 | -0.04 | $-94,419,000 | |
| 11/09/2023 | Q3 2023 | -$0.51 | -$0.43 | 0.08 | $0 | |
| 08/03/2023 | Q2 2023 | -$0.54 | -$0.43 | 0.11 | $94.42 M | |
| 05/04/2023 | Q1 2023 | -$0.54 | $40.16 | 40.7 | $0 | |
| 03/06/2023 | Q4 2022 | -$0.58 | -$0.47 | 0.11 | $456 | |
| 11/10/2022 | Q3 2022 | -$0.48 | -$0.47 | 0.01 | $153,333 | $38,380 |
| 08/10/2022 | Q2 2022 | -$0.52 | -$0.44 | 0.08 | $196,800 | $94,419 |
| 05/10/2022 | Q1 2022 | -$0.44 | -$0.49 | -0.05 | $183,698 | |
| 03/10/2022 | Q4 2021 | -$0.39 | -$0.42 | -0.03 | $189,591 | |
| 11/09/2021 | Q3 2021 | -$0.61 | -$0.47 | 0.14 | $700,000 | $482,130 |
| 09/09/2021 | Q2 2021 | -$1.44 | -$0.33 | 1.11 | $725,000 | $660,040 |
| 03/30/2021 | Q1 2021 | -$0.46 | $748,200 | |||
| 12/30/2020 | Q4 2020 | -$0.43 | $665,080 | |||
| 09/29/2020 | Q3 2020 | -$0.33 | $682,570 | |||
| 06/29/2020 | Q2 2020 | -$0.27 | $480,835 | |||
| 03/30/2020 | Q1 2020 | -$0.24 | $483,050 |
Immuneering Corporation Earnings: Frequently Asked Questions
-
When is Immuneering Corporation's earnings date?
Immuneering Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
Did Immuneering Corporation beat their earnings estimates last quarter?
In the previous quarter, Immuneering Corporation (:IMRX) reported $-0.47 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.51 by $0.04.
-
How can I listen to Immuneering Corporation's earnings conference call?
The conference call for Immuneering Corporation's latest earnings report can be listened to online.
-
How can I read Immuneering Corporation's conference call transcript?
The conference call transcript for Immuneering Corporation's latest earnings report can be read online.
-
How much profit does Immuneering Corporation generate each year?
Immuneering Corporation (:IMRX) has a recorded net income of $0. Immuneering Corporation has generated $-1.88 earnings per share over the last four quarters.
-
What is Immuneering Corporation's price-to-earnings ratio?
Immuneering Corporation (:IMRX) has a price-to-earnings ratio of -1.41 and price/earnings-to-growth ratio is 2.63.
